Cite
HARVARD Citation
Orlowski, R. et al. (2016). Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma. Cancer. 122 (13), pp. 2050-2056. [Online].